To include your compound in the COVID-19 Resource Center, submit it here.

TG Therapeutics completes enrollment in Phase III UNITY-CLL trial

TG Therapeutics Inc. (NASDAQ:TGTX) completed enrollment in the Phase III UNITY-CLL trial evaluating ublituximab (TG-1101, TGTX-1101) in combination with TGR-1202 (umbralisib) to treat chronic

Read the full 240 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE